Financial Data and Key Metrics Changes - Revenue for Q1 2024 increased by 12.9% to $41.4 million compared to the same period last year, with a gross profit of $32.6 million and a gross margin of 78.8% [8][22] - Total operating expenses rose by 3.8% to $37.2 million, while net loss decreased to $6.6 million or $0.15 per share, compared to a net loss of $7.1 million or $0.17 per share in Q1 2023 [23][24] - Adjusted EBITDA improved to $1 million from an adjusted EBITDA loss of $3.8 million in the previous year, indicating enhanced operational efficiency [24] Business Line Data and Key Metrics Changes - The growth was broad-based across products and applications, with a 4.9% increase in unit volume, a 5.3% mix favorability, and a 2.6% increase in price contributing to revenue growth [22] - Core accounts, defined as those generating over $100,000 in revenue, represented approximately 65% of total revenue, with the largest core accounts exceeding $1 million annually [10] Market Data and Key Metrics Changes - The company noted a shift in the timing of elective outpatient procedures, with a strong performance in January and February, followed by a volume uptick in April instead of March [7][27] - The company continues to see growth in the trauma and breast neurotization segments, with increasing demand for the Resensation technique [45] Company Strategy and Development Direction - The growth strategy focuses on deepening relationships with existing core accounts and expanding into new clinical applications [10][11] - The company is on track for the BLA filing for Avance nerve grafts in Q3 2024, which could lead to market exclusivity for 12 years upon approval [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2024 revenue guidance, maintaining a range of $177 million to $181 million, representing an annual growth rate of approximately 11% to 14% [24] - The management highlighted the importance of innovation and expanding the nerve protection portfolio as key growth drivers [12][13] Other Important Information - The company has made strategic changes to its financial reporting, including the removal of revenue breakdowns between scheduled and emergent trauma applications, to better align with its commercial strategy [9][21] - The company is focused on optimizing resource allocation and achieving profitability while continuing to invest in innovation [24] Q&A Session Summary Question: Can you provide color on performance through the quarter, particularly in March? - Management noted that the typical step-up in volume occurred in April instead of March, possibly due to the timing of Easter holidays, but overall growth across products was maintained [27][29] Question: What is the status of the CEO search? - The CEO search is ongoing, led by independent directors with an outside search firm, and an announcement will be made once finalized [31] Question: Can you elaborate on the decision to remove the scheduled versus emerging breakdown? - The decision was based on the conclusion that the previous disclosure did not provide the best insights into the business model and commercial strategy, which focuses on increasing penetration into high potential accounts [34] Question: What is the expected contribution from new product launches in 2024? - New products are included in the guidance, with expectations for modest revenue impact in the second half of the year as they go through value analysis committees [38] Question: How is procedure growth looking in the quarter? - Management reported good procedure growth across segments, particularly in trauma and breast neurotization, with continued interest from surgeons [44]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Ex ...

AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of 33.33%.Over the last four quarters, the company ha ...

Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA and TAMPA, FL – May 2, 2024 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results • First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023. • In the first quarter of 2024, our gross margin in ...

ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. "We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries," said Karen Zaderej, chairman, CEO, and president ...

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may ...

AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript March 5, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Chris Pasquale - Nephron Mike Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Dave Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Confere ...

Table of Content . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Companies displaying incessant earnings growth will continue to captivate almost everyone in the investment world, from top brass to research analysts. This is because earnings are a measure of the money a company is making. Still, earnings acceleration works better when lifting the stock price.Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in the stock price. Some of the notable companies to have witnessed solid earnings acceleration as of now are Prot ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...